ClinicalTrials.gg
CompletedNCT01015118Updated Dec 7, 2017Results posted

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

A Phase 3 interventional study of Placebo and Paclitaxel in Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Boehringer Ingelheim. Completed at 281 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,366
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Ovarian Neoplasms with a site in Germany — 35 open to participants now, 55 under way, 19 of them phase 3. Ovarian Neoplasms · Germany.

Enrollment
9th of 163
1,366 · median 254
Started
2009
with 6 others
Phase 3
58 of 189
9 open now
Registered
50th of 189
by date

Among the 189 studies in Ovarian Neoplasms with a site in Germany, this one is the 9th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2009, is one of 58 in phase 3, and was the 50th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

35 of the 189 studies in Ovarian Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Ovarian Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

03

Conditions studied

  • Ovarian Neoplasms
  • Peritoneal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • first diagnosis of confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  • International Federation of Gynecology and Obstetrics (FIGO) Stages IIB - IV
  • females, age 18 years or older
  • of at least 6 months
  • (ECOG) performance status 0, 1 or 2
  • prior surgery, defined as either (a) debulking surgery with maximum surgical effort at cytoreduction with the goal of no residual disease or (b) or limited surgery in patients with stage IV disease for whom surgical debulking was not considered appropriate, if diagnosis is confirmed by histology and no surgery is planned prior to disease progression (including interval debulking surgery)
  • patient has given written which must be consistent with the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local legislation
  • planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery

Exclusion criteria

Exclusion criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum
  • planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery
  • non-healing wound, ulcer or bone fracture
  • clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration
  • pre-existing sensory or motor neuropathy (CTCAE) grade 2 or higher, except due to trauma
  • history of major thromboembolic event
  • known inherited or acquired bleeding disorder
  • significant cardiovascular diseases
  • clinically relevant pericardial effusion
  • history of a cerebral vascular accident, or subarachnoid haemorrhage within the past 6 months
  • inadequate safety laboratory values
  • serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including , , (HIV)
  • poorly controlled diabetes mellitus or other to high dose therapy
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • other diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer
  • prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy)
  • prior systemic cytotoxic chemotherapy
  • prior treatment with BIBF 1120 or any other angiogenesis inhibitor
  • prior radiotherapy
  • serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration
  • Women of who are sexually active and not using a highly effective method of during the trial and for at least twelve months after the end of active therapy.
  • pregnancy or breast feeding
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • active alcohol or drug abuse
  • patients unable to comply with the protocol
  • any contraindications for therapy with paclitaxel or carboplatin
  • treatment with other drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,366 participants (actual)

Study arms

  • Experimental
    BIBF 1120

    patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel

    Drug: BIBF 1120 · Drug: Paclitaxel · Drug: Carboplatin

  • Placebo comparator
    Placebo

    patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel

    Drug: Placebo · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • DrugPlacebo

    comparator to BIBF 1120

  • Paclitaxel (standard chemo-therapy)

  • comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)

  • Carboplatin (standard chemo-therapy)

  • Paclitaxel (standard chemo-therapy)

  • Carboplatin (standard chemo-therapy)

06

What researchers measure

Primary outcomes

  1. PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.

    Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: First drug administration to date of disease progression or death whichever occurs first , upto 29 months

  2. PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).

    Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months

Secondary outcomes

  1. PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).

    Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: First drug administration to date of disease progression or death whichever occurs first , upto 29 months

  2. PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).

    Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months

  3. Overall Survival

    Overall survival is defined as time from randomization to date of death (irrespective of reason). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    Time frame: First drug administration to date of death until final DBL 26September16, upto 62 months

  4. Time to CA-125 Tumour Marker Progression

    Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 \>=2 x nadir in case nadir value \> Upper limit of normal (ULN) or CA-125 \>=2 x ULN in case nadir value \<= ULN.

    Time frame: First drug administration until final DBL 26September16, upto 62 months

  5. Objective Response Based on Investigator Assessment

    Objective tumour response defined as either complete response \[CR\] or partial response \[PR\] in patients with at least 1 target lesion reported at baseline

    Time frame: First drug administration until final DBL 26September16, upto 62 months

  6. Change in Abdominal/Gastro-intestinal Symptoms Over Time

    Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28). As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).

    Time frame: First drug administration until final DBL 26September16, upto 62 months

  7. Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.

    Change in Global Health Status/ Quality of life (QoL) over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure. As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).

    Time frame: First drug administration until final DBL 26September16, upto 62 months

07

Results

Posted Jan 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneNintedanibPlacebo
Started911455
Completed242128
Not completed669327
Withdrew: Protocol violation56
Withdrew: Withdrawal by subject10327
Withdrew: Other adverse event (ae)14133
Withdrew: Worsening or ae of underlying disease54
Withdrew: Progressive disease364229
Withdrew: Not treated95
Withdrew: Other than stated above4223

Outcome measures

PrimaryPFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.

Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
First drug administration to date of disease progression or death whichever occurs first , upto 29 months
Reported as:
Median · Months
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.
MonthsNintedanibPlacebo
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.17.2 (11.1 to 32.5)16.6 (10.8 to 30.4)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.0239 · Hazard ratio (hr): 0.84 · 95% CI 0.72 to 0.98If hazard ratio is below 1 then favours nintedanib.
PrimaryPFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).

Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months
Reported as:
Median · Months
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).
MonthsNintedanibPlacebo
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).17.6 (11.1 to 38.0)16.6 (10.8 to 37.3)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.0286 · Hazard ratio (hr): 0.86 · 95% CI 0.75 to 0.98If hazard ratio is below 1 then favours nintedanib.
SecondaryPFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).

Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
First drug administration to date of disease progression or death whichever occurs first , upto 29 months
Reported as:
Median · Months
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).
MonthsNintedanibPlacebo
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).18.3 (11.1 to 32.5)16.6 (10.8 to 30.4)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.0186 · Hazard ratio (hr): 0.83 · 95% CI 0.72 to 0.97If hazard ratio is below 1 then favours nintedanib.
SecondaryPFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).

Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months
Reported as:
Median · Months
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).
MonthsNintedanibPlacebo
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).18.4 (11.1 to 38.5)16.6 (10.8 to 37.3)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.0256 · Hazard ratio (hr): 0.85 · 95% CI 0.74 to 0.98If hazard ratio is below 1 then favours nintedanib.
SecondaryOverall Survival

Overall survival is defined as time from randomization to date of death (irrespective of reason). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Time frame:
First drug administration to date of death until final DBL 26September16, upto 62 months
Reported as:
Median · Months
Overall Survival
MonthsNintedanibPlacebo
Overall Survival62.0 (30.0 to NA)62.8 (30.6 to NA)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.8653 · Hazard ratio (hr): 0.99 · 95% CI 0.83 to 1.17If hazard ratio is below 1 then favours nintedanib.
SecondaryTime to CA-125 Tumour Marker Progression

Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 \>=2 x nadir in case nadir value \> Upper limit of normal (ULN) or CA-125 \>=2 x ULN in case nadir value \<= ULN.

Time frame:
First drug administration until final DBL 26September16, upto 62 months
Reported as:
Median · Months
Time to CA-125 Tumour Marker Progression
MonthsNintedanibPlacebo
Time to CA-125 Tumour Marker Progression16.6 (10.6 to 47.0)14.1 (8.6 to 42.6)
Statistical analysis
  • Nintedanib vs Placebo · Log Rank · p = 0.0749 · Hazard ratio (hr): 0.88 · 95% CI 0.77 to 1.01If hazard ratio is below 1 then favours nintedanib.
SecondaryObjective Response Based on Investigator Assessment

Objective tumour response defined as either complete response \[CR\] or partial response \[PR\] in patients with at least 1 target lesion reported at baseline

Time frame:
First drug administration until final DBL 26September16, upto 62 months
Reported as:
Number · percentage of participants
Objective Response Based on Investigator Assessment
percentage of participantsNintedanibPlacebo
Objective Response Based on Investigator Assessment74.370.2
Statistical analysis
  • Nintedanib vs Placebo · Regression, Logistic · p = 0.3490 · Odds ratio (or): 1.22 · 95% CI 0.81 to 1.82An odds ratio \>1 favours nintedanib.
SecondaryChange in Abdominal/Gastro-intestinal Symptoms Over Time

Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28). As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).

Time frame:
First drug administration until final DBL 26September16, upto 62 months
Reported as:
Mean · units on a scale
Change in Abdominal/Gastro-intestinal Symptoms Over Time
units on a scaleNintedanibPlacebo
Change in Abdominal/Gastro-intestinal Symptoms Over Time24.63 ± 0.4919.34 ± 0.64
Statistical analysis
  • Nintedanib vs Placebo · Mixed effect growth curve model · p = <0.0001 · Mean difference (net): 5.29 · 95% CI 3.88 to 6.69Mean difference presented is the Adjusted mean difference. Difference calculated as nintedanib minus placebo. High values represent a worse level of symptoms.
SecondaryChange in Global Health Status/ Quality of Life (QoL) Scale Over Time.

Change in Global Health Status/ Quality of life (QoL) over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure. As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).

Time frame:
First drug administration until final DBL 26September16, upto 62 months
Reported as:
Mean · units on a scale
Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
units on a scaleNintedanibPlacebo
Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.68.79 ± 0.4870.67 ± 0.65
Statistical analysis
  • Nintedanib vs Placebo · Mixed effect growth curve model · p = 0.0124 · Mean difference (net): -1.88 · 95% CI -3.35 to -0.41Mean difference calculated is the Adjusted mean. High values represent a better level of functioning. Difference calculated as nintedanib minus placebo.

Adverse events

Collected over First drug administration until data cut-off 26September16, up to 62 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—157/450 (34.9%)442/450 (98.2%)
Nintedanib—379/902 (42%)891/902 (98.8%)
Most frequent serious events
Showing 10 of 376
Most frequent serious events
EventPlaceboNintedanib
DiarrhoeaGastrointestinal disorders8/45041/902
AnaemiaBlood and lymphatic system disorders9/45036/902
VomitingGastrointestinal disorders12/45033/902
Abdominal painGastrointestinal disorders6/45030/902
NeutropeniaBlood and lymphatic system disorders6/45024/902
NauseaGastrointestinal disorders10/45024/902
PyrexiaGeneral disorders8/45023/902
ThrombocytopeniaBlood and lymphatic system disorders6/45021/902
DehydrationMetabolism and nutrition disorders6/45021/902
ConstipationGastrointestinal disorders10/45013/902
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPlaceboNintedanib
DiarrhoeaGastrointestinal disorders114/450692/902
NauseaGastrointestinal disorders231/450583/902
AlopeciaSkin and subcutaneous tissue disorders278/450519/902
NeutropeniaBlood and lymphatic system disorders203/450419/902
FatigueGeneral disorders201/450388/902
VomitingGastrointestinal disorders119/450391/902
AnaemiaBlood and lymphatic system disorders129/450317/902
ConstipationGastrointestinal disorders151/450254/902
ThrombocytopeniaBlood and lymphatic system disorders87/450301/902
Abdominal painGastrointestinal disorders111/450281/902

Baseline characteristics

Randomised Set (RS): included all randomised patients, regardless of whether or not they had received treatment. Patients were assigned to nintedanib or placebo as randomised.

Age, Continuous
Age, Continuous(Years)NintedanibPlaceboTotal
Mean57.5 ± 11.056.9 ± 11.157.3 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)NintedanibPlaceboTotal
Female9114551366
Male000
08

Study locations

281 sites
  • 1199.15.10113 Boehringer Ingelheim Investigational Site
    Tucson, Arizona, United States
  • 1199.15.10030 Boehringer Ingelheim Investigational Site
    Long Beach, California, United States
  • 1199.15.10001 Boehringer Ingelheim Investigational Site
    Santa Rosa, California, United States
  • 1199.15.10005 Boehringer Ingelheim Investigational Site
    Englewood, Colorado, United States
  • 1199.15.10028 Boehringer Ingelheim Investigational Site
    New Haven, Connecticut, United States
  • 1199.15.10014 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1199.15.10010 Boehringer Ingelheim Investigational Site
    Augusta, Georgia, United States
  • 1199.15.10004 Boehringer Ingelheim Investigational Site
    Savannah, Georgia, United States
  • 1199.15.10011 Boehringer Ingelheim Investigational Site
    Louisville, Kentucky, United States
  • 1199.15.10003 Boehringer Ingelheim Investigational Site
    Marrero, Louisiana, United States
  • 1199.15.10017 Boehringer Ingelheim Investigational Site
    Detroit, Michigan, United States
  • 1199.15.10103 Boehringer Ingelheim Investigational Site
    Minneapolis, Minnesota, United States
  • 1199.15.10002 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 1199.15.10012 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 1199.15.10020 Boehringer Ingelheim Investigational Site
    Winston-Salem, North Carolina, United States
  • 1199.15.10019 Boehringer Ingelheim Investigational Site
    Bismarck, North Dakota, United States
  • 1199.15.10024 Boehringer Ingelheim Investigational Site
    Canton, Ohio, United States
  • 1199.15.10025 Boehringer Ingelheim Investigational Site
    Cleveland, Ohio, United States
  • 1199.15.10029 Boehringer Ingelheim Investigational Site
    Cleveland, Ohio, United States
  • 1199.15.10021 Boehringer Ingelheim Investigational Site
    Portland, Oregon, United States
  • 1199.15.10013 Boehringer Ingelheim Investigational Site
    Abington, Pennsylvania, United States
  • 1199.15.10016 Boehringer Ingelheim Investigational Site
    Allentown, Pennsylvania, United States
  • 1199.15.10008 Boehringer Ingelheim Investigational Site
    Providence, Rhode Island, United States
  • 1199.15.10102 Boehringer Ingelheim Investigational Site
    Greenville, South Carolina, United States
  • 1199.15.10006 Boehringer Ingelheim Investigational Site
    Chattanooga, Tennessee, United States
  • 1199.15.10104 Boehringer Ingelheim Investigational Site
    Austin, Texas, United States
  • 1199.15.10100 Boehringer Ingelheim Investigational Site
    Bedford, Texas, United States
  • 1199.15.10107 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 1199.15.10108 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 1199.15.10110 Boehringer Ingelheim Investigational Site
    Fort Worth, Texas, United States
  • 1199.15.10007 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1199.15.10105 Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
  • 1199.15.10112 Boehringer Ingelheim Investigational Site
    Vancouver, Washington, United States
  • 1199.15.61006 Boehringer Ingelheim Investigational Site
    Camperdown, New South Wales, Australia
  • 1199.15.61001 Boehringer Ingelheim Investigational Site
    Waratah, New South Wales, Australia
  • 1199.15.61004 Boehringer Ingelheim Investigational Site
    Herston, Queensland, Australia
  • 1199.15.61003 Boehringer Ingelheim Investigational Site
    Southe Brisbane, Queensland, Australia
  • 1199.15.61005 Boehringer Ingelheim Investigational Site
    North Terrace, South Australia, Australia
  • 1199.15.61007 Boehringer Ingelheim Investigational Site
    Parkville, Victoria, Australia
  • 1199.15.61002 Boehringer Ingelheim Investigational Site
    Nedlands, Western Australia, Australia
  • 1199.15.43003 Boehringer Ingelheim Investigational Site
    Graz, Austria
  • 1199.15.43001 Boehringer Ingelheim Investigational Site
    Innsbruck, Austria
  • 1199.15.43011 Boehringer Ingelheim Investigational Site
    Krems, Austria
  • 1199.15.43007 Boehringer Ingelheim Investigational Site
    Kufstein, Austria
  • 1199.15.43005 Boehringer Ingelheim Investigational Site
    Linz, Austria
  • 1199.15.43010 Boehringer Ingelheim Investigational Site
    Salzburg, Austria
  • 1199.15.43013 Boehringer Ingelheim Investigational Site
    Wels, Austria
  • 1199.15.43002 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.15.43012 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.15.32010 Boehringer Ingelheim Investigational Site
    Edegem, Belgium
  • 1199.15.32012 Boehringer Ingelheim Investigational Site
    Hasselt, Belgium
  • 1199.15.32003 Boehringer Ingelheim Investigational Site
    La Louvière, Belgium
  • 1199.15.32001 Boehringer Ingelheim Investigational Site
    Leuven, Belgium
  • 1199.15.32007 Boehringer Ingelheim Investigational Site
    Liège, Belgium
  • 1199.15.32008 Boehringer Ingelheim Investigational Site
    Sint-Niklaas, Belgium
  • 1199.15.11005 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1199.15.11004 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1199.15.11008 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1199.15.11009 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • 1199.15.11003 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1199.15.11006 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1199.15.11001 Boehringer Ingelheim Investigational Site
    Sherbrooke, Quebec, Canada
  • 1199.15.42002 Boehringer Ingelheim Investigational Site
    Brno, Czechia
  • 1199.15.42003 Boehringer Ingelheim Investigational Site
    Olomouc, Czechia
  • 1199.15.42001 Boehringer Ingelheim Investigational Site
    Prague, Czechia
  • 1199.15.45004 Boehringer Ingelheim Investigational Site
    Aalborg, Denmark
  • 1199.15.45002 Boehringer Ingelheim Investigational Site
    Herlev, Denmark
  • 1199.15.45005 Boehringer Ingelheim Investigational Site
    Herning, Denmark
  • 1199.15.45001 Boehringer Ingelheim Investigational Site
    Købenahvn Ø, Denmark
  • 1199.15.45003 Boehringer Ingelheim Investigational Site
    Odense C, Denmark
  • 1199.15.35801 Boehringer Ingelheim Investigational Site
    Helsinki, Finland
  • 1199.15.35804 Boehringer Ingelheim Investigational Site
    Jyväskylä, Finland
  • 1199.15.35805 Boehringer Ingelheim Investigational Site
    Kuopio, Finland
  • 1199.15.35803 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 1199.15.35802 Boehringer Ingelheim Investigational Site
    Tampere, Finland
  • 1199.15.33047 Boehringer Ingelheim Investigational Site
    Aix-en-Provence, France
  • 1199.15.33035 Boehringer Ingelheim Investigational Site
    Avignon cedex 02, France
  • 1199.15.33055 Boehringer Ingelheim Investigational Site
    Besançon, France
  • 1199.15.33003 Boehringer Ingelheim Investigational Site
    Bordeaux cedex, France
  • 1199.15.33004 Boehringer Ingelheim Investigational Site
    Bordeaux, France
  • 1199.15.33006 Boehringer Ingelheim Investigational Site
    Caen cedex 5, France
  • 1199.15.33025 Boehringer Ingelheim Investigational Site
    Clermont-Ferrand cedex, France
  • 1199.15.33048 Boehringer Ingelheim Investigational Site
    Dechy, France
  • 1199.15.33042 Boehringer Ingelheim Investigational Site
    Fréjus, France
  • 1199.15.33037 Boehringer Ingelheim Investigational Site
    La Roche-Sur-Yon cedex 09, France
  • 1199.15.33008 Boehringer Ingelheim Investigational Site
    Le Mans, France
  • 1199.15.33009 Boehringer Ingelheim Investigational Site
    Lille cedex, France
  • 1199.15.33020 Boehringer Ingelheim Investigational Site
    Lyon, France
  • 1199.15.33011 Boehringer Ingelheim Investigational Site
    Marseille cedex 09, France
  • 1199.15.33021 Boehringer Ingelheim Investigational Site
    Monaco Cedex, France
  • 1199.15.33012 Boehringer Ingelheim Investigational Site
    Mont-de-Marsan cedex, France
  • 1199.15.33052 Boehringer Ingelheim Investigational Site
    Montpellier cedex 5, France
  • 1199.15.33053 Boehringer Ingelheim Investigational Site
    Mougins, France
  • 1199.15.33038 Boehringer Ingelheim Investigational Site
    Nancy, France
  • 1199.15.33013 Boehringer Ingelheim Investigational Site
    Nantes cedex 02, France
  • 1199.15.33015 Boehringer Ingelheim Investigational Site
    Orléans cedex 02, France
  • 1199.15.33027 Boehringer Ingelheim Investigational Site
    Paris cedex 20, France
  • 1199.15.33001 Boehringer Ingelheim Investigational Site
    Paris, France
  • 1199.15.33051 Boehringer Ingelheim Investigational Site
    PERIGUEUX Cedex, France
  • 1199.15.33030 Boehringer Ingelheim Investigational Site
    Plerin SUR MER, France

Showing the first 100 of 281 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjorge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16. PubMed 26590673 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Apr 2013, 40 months.

Results were first posted in Jan 2015, 1 year 9 months after primary completion. A results delay was requested in Mar 2014.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 40 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2009
First posted
Nov 18, 2009
StartActual
Nov 17, 2009
Primary completionActual
Apr 1, 2013
CompletionActual
Sep 15, 2016
Results delay requested
Mar 27, 2014
Results first posted
Jan 15, 2015
Last update
Dec 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01015118
Responsible party
Sponsor
First posted
Nov 18, 2009
Start date
Nov 17, 2009
Primary completion
Apr 1, 2013
Completion
Sep 15, 2016
Results posted
Jan 15, 2015
Last update
Dec 7, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion